冻干粉 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-04 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Common analytical approaches include reversed-phase high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Peptide mapping after enzymatic digestion can verify the expected sequence. Immunoassays may be used to measure the compound or its downstream markers, but they can cross-react with related peptides and require careful validation. Impurity profiles typically include truncated sequences, oxidized methionine residues, and residual solvents from synthesis. Each method reports a different property, so no single assay establishes overall quality.
Storage claims vary across suppliers, and published stability data for specific formulations are limited. Extrapolating from related peptides is common but not a substitute for direct measurement. For research use, documentation such as a certificate of analysis is often requested to confirm identity and purity. What constitutes an acceptable purity threshold depends on the intended application. Open questions remain about how temperature excursions during shipping affect long-term peptide integrity. Independent verification by an end user is not routinely reported.
Lyophilized tesamorelin is generally stored refrigerated at 2 to 8 degrees Celsius, protected from light and moisture. Peptides in this class are often kept frozen at minus 20 degrees Celsius for longer periods. Reconstituted solutions are typically used within a defined window because hydrolysis and oxidation proceed faster in liquid form. Container material and headspace also influence how long a preparation retains its expected profile. Specific stability figures depend on concentration and buffer composition.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
纯度与身份确认依赖色谱与质谱的组合。反相高效液相色谱在 214 nm 紫外检测下分离主峰与相关杂质，给出纯度百分比与保留时间；电喷雾或基质辅助激光解吸电离质谱提供分子量，用于确认 N 端修饰是否完整。序列层面可通过肽图或氨基酸分析验证。含量测定常用紫外吸收法或氮元素分析，不同方法之间需要做交叉校验。
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
研究用与临床用材料的标准并不相同。质量控制通常覆盖纯度、残留溶剂、反离子含量、微生物限度与内毒素水平，各项均有对应检测方法。随货文件应包含批号、检测项目、方法与结果，使数据可以追溯。核验时应关注纯度是否按主峰面积计算、杂质是否已定性、方法是否经过验证，这些信息决定结果能否被外部重复。
=== Annual conference === Every year, the E.S.PKU and a member country host a conference. The conference takes place in a different country every year and typically has 450-550 participants. The conference takes place at the end of the year and starts on a Thursday, ending on Sunday. There are three separate conference tracks for patients and families, professionals and delegates. The last conference took place in November and was located in Venice, Italy and got some media attention.
==== Modern interpretations ==== The interpretation of dependent origination as mainly referring to mental processes has been defended by various modern scholars such as Eviatar Shulman and Collett Cox. Eviatar Shulman argues that dependent origination only addresses "the way the mind functions in samsara, the processes of mental conditioning that transmigration consists of." He further argues that it "should be understood to be no more than an inquiry into the nature of the self (or better, the lack of a self)." Shulman grants that there are some ontological implications that may be gleaned from dependent origination. However, he argues that at its core dependent origination is concerned with "identifying the different processes of mental conditioning and describing their relations". For Shulman, dependent origination does not "deal with how things exist, but with the processes by which the mind operates." Shulman argues that the general principle of dependent origination deals exclusively with the processes outlined in the lists of nidanas (not with existence per se, and certainly not with all objects). Shulman writes that seeing dependent origination as referring to the nature of reality in general "means investing the words of the earlier teachings with meanings derived from later Buddhist discourse" which leads to a misrepresentation of early Buddhism. Sue Hamilton presents a similar interpretation which sees dependent origination as showing how all things and indeed our entire "world" (of experience) are dependently originated through our cognitive apparatus.
=== Autoimmunity treatment === Acting as DAMPs, HSPs can extracellularly promote autoimmune reactions leading to diseases as rheumatoid arthritis or systemic lupus erythematosus. Nevertheless, it was found, that application of some HSPs into patients is able to induce immune tolerance and treat autoimmune diseases. The underlying mechanism is not known. HSPs (especially hsp60 and hsp70) are used in clinical studies to treat rheumatoid arthritis and type 1 diabetes. Current therapeutic research areas in the treatment for DM include: long-term physical exercise, hot tub therapy (HTT), and alfalfa-derived HSP70 (aHSP70). Hsp90 inhibitors are another possible treatment for autoimmunity, because hsp90 is necessary for proper folding of many pro-inflammatory proteins (components of PI3K, MAPK and NF-kB cascades).
=== Microscopy === Another principal tool in the diagnosis of infectious disease is microscopy. Virtually all of the culture techniques discussed above rely, at some point, on microscopic examination for definitive identification of the infectious agent. Microscopy may be carried out with simple instruments, such as the compound light microscope, or with instruments as complex as an electron microscope. Samples obtained from patients may be viewed directly under the light microscope, and can often rapidly lead to identification. Microscopy is often also used in conjunction with biochemical staining techniques, and can be made exquisitely specific when used in combination with antibody based techniques. For example, the use of antibodies made artificially fluorescent (fluorescently labeled antibodies) can be directed to bind to and identify a specific antigens present on a pathogen. A fluorescence microscope is then used to detect fluorescently labeled antibodies bound to internalized antigens within clinical samples or cultured cells. This technique is especially useful in the diagnosis of viral diseases, where the light microscope is incapable of identifying a virus directly. Other microscopic procedures may also aid in identifying infectious agents. Almost all cells readily stain with a number of basic dyes due to the electrostatic attraction between negatively charged cellular molecules and the positive charge on the dye. A cell is normally transparent under a microscope, and using a stain increases the contrast of a cell with its background.
Sources: en.wikipedia.org
In September 1971, Mazda introduced the "Mazda Grand Familia" and the Mazda Savanna to better compete with the Toyota Corolla, and the Nissan Sunny in North America. The Grand Familia/Savanna was intended to replace the smaller Familia. But with the advent of the 1970s energy crisis, the Familia began to experience an increase in sales due to better fuel economy, so the Familia remained in Japan and Europe, and Mazda decided to offer the Grand Familia and Savanna as larger, performance enhanced alternatives. It is better known by its export market names Mazda 808, 818, and RX-3. The Grand Familia was also built by Kia with the 1272 cc engine from October 1975, originally as the Brisa II and later as the K303.
=== Bu === John Buchanan (1917–2007). American biochemist at MIT, best known for his research on the biosynthesis of purines. Member Natl. Acad. Sci. USA. Eduard Buchner (1860–1917). German chemist and physiologist at LMU Munich, who overthrew the doctrine of vitalism by showing that cell-free yeast extract could catalyse fermentation, a discovery described by Arthur Kornberg as the beginning of biochemistry. 1907 Nobel Prize in Chemistry. Dean Burk (1904–1988). American biochemist at the Fixed Nitrogen Research Laboratory, co-discoverer of biotin. He is credited (with Hans Lineweaver) with introducing the double-reciprocal plot in kinetics. He became a vociferous opponent of water fluoridation. Robert H. Burris (1914–2010). American biochemist at the University of Wisconsin–Madison, expert on nitrogen fixation. Member Natl. Acad. Sci. USA. Stephen Busby (DPhil 1975) FRS, biochemist at the University of Birmingham. Carlos Bustamante (b. 1951). Peruvian-American biophysicist at UC Berkeley. Known for single-molecule studies, including the use of optical tweezers for measuring the forces that maintain biological structures. Member Natl. Acad. Sci. USA.
== Public image == Kardashian has received criticism and negative comments which were focused on her body since Keeping Up with the Kardashians premiered in 2007. She has been compared to her sisters Kourtney and Kim with Kardashian recalling "I didn't really realize that I was 'the fat sister' if you will until I went on TV and the media started saying that about me. I knew I didn't look like my sisters and I didn't have those shapes, but I didn't think that was wrong". Kardashian's physique, notably her face, has attracted significant attention from the media and public in recent years. She has received comments from the public regularly saying she looks "unrecognisable". However, Kardashian has denied having surgery, stating that when she lost weight she lost fat in her face and also credits her make-up artist. She has also been open to using photo editing app Facetune, and stated "Facetune is the best thing to bring to the table. It's life-changing" in February 2016.
=== Overview === The Office of Alternative Medicine (OAM) was established in October 1991 by the United States Congress. The OAM was expanded from an office into a center and renamed the National Center for Complementary and Alternative Medicine (NCCAM) in October 1998. It is one of several centers within the National Institutes of Health (NIH). The founding director of the center was Stephen Straus. In 2008, Josephine Briggs became the second director of NCCAM. The NCCAM was renamed the National Center for Complementary and Integrative Health (NCCIH) in December 2014. Helene Langevin was director from August 2018 to November 2025. The 2014 name change to NCCIH has been described by critics as an attempt by the center to mitigate criticism by avoiding the term "alternative" and distancing itself from having funded studies of questionable merit. The 2001 mission statement of the NCCAM stated that it was "dedicated to exploring complementary and alternative healing practices in the context of rigorous science; training complementary and alternative medicine researchers; and disseminating authoritative information to the public and professionals." As NCCIH, the mission statement is "to define, through rigorous scientific investigation, the usefulness and safety of complementary and alternative medicine interventions and their roles in improving health and health care".
Abelacimab (MAA868), is a fully human monoclonal antibody for the treatment of thrombosis, under development by Anthos Therapeutics. It is anti-factor XI antibody. The hope behind its development is that factor XI plays a bigger role in thrombosis (via the intrinsic/contact activation pathway) than hemostasis, so targeting it might reduce clotting risks without a corresponding increase in bleeding. It has, indeed, shown overwhelming reduction in bleeding as compared to a direct oral anticoagulant (rivaroxaban) in patients with atrial fibrillation and a moderate-to-high risk of stroke. Data is insufficient for drawing a conclusion on whether it increases or decreases stroke events as compared to rivaroxaban. Antibody Monoclonal antibody Immunology
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
Refrigeration between 2 and 8 degrees Celsius with protection from light is the common recommendation. Many laboratories choose frozen storage at minus 20 degrees Celsius when the material will not be used soon. Repeated temperature cycling is generally avoided.